The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Illumina to Announce First Quarter 2011 Financial Results on Tuesday, April 26, 2011

Tuesday, April 12, 2011

Illumina to Announce First Quarter 2011 Financial Results on Tuesday, April 26, 201106:00 EDT Tuesday, April 12, 2011 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for first quarter 2011 following the close of market on Tuesday, April 26, 2011. On the same day, at 2:30pm Pacific Time (5:30pm Eastern Time), Jay Flatley, President and Chief Executive Officer, and Christian Henry, Senior Vice President, Chief Financial Officer, and General Manager, Life Sciences, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:30pm Pacific Time (5:30pm Eastern Time) on Tuesday, April 26, 2011. Interested parties may listen to the call by dialing 866-543-6411 (passcode: 85631425), or if outside North America, by dialing +1-617-213-8900 (passcode: 85631425). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com. A replay of the conference call will be available from 6:30pm Pacific Time (9:30pm Eastern Time) on April 26, 2011 through May 3, 2011 by dialing 888-286-8010 (passcode: 66177006), or if outside North America, by dialing +1-617-801-6888 (passcode: 66177006). About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Illumina, Inc.Investors:Peter J. Fromen, Sr. Director, Investor Relations+858-202-4507pfromen@illumina.comorMedia:Wilson Grabill, Sr. Manager, Public Relations+858-882-6822wgrabill@illumina.com